Consolidated Planning Corp Purchases 407 Shares of Boston Scientific Corporation (NYSE:BSX)

Consolidated Planning Corp increased its position in Boston Scientific Corporation (NYSE:BSX) by 0.8% in the 1st quarter, HoldingsChannel.com reports. The fund owned 49,180 shares of the medical equipment provider’s stock after acquiring an additional 407 shares during the quarter. Consolidated Planning Corp’s holdings in Boston Scientific were worth $4,961,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of BSX. Vanguard Group Inc. lifted its position in Boston Scientific by 1.2% during the fourth quarter. Vanguard Group Inc. now owns 132,890,784 shares of the medical equipment provider’s stock valued at $11,869,805,000 after purchasing an additional 1,600,062 shares in the last quarter. Wellington Management Group LLP lifted its position in Boston Scientific by 10.2% during the fourth quarter. Wellington Management Group LLP now owns 36,165,399 shares of the medical equipment provider’s stock valued at $3,230,293,000 after purchasing an additional 3,344,571 shares in the last quarter. Geode Capital Management LLC lifted its position in Boston Scientific by 3.5% during the fourth quarter. Geode Capital Management LLC now owns 30,626,170 shares of the medical equipment provider’s stock valued at $2,729,371,000 after purchasing an additional 1,041,329 shares in the last quarter. Capital World Investors lifted its position in Boston Scientific by 28.7% during the fourth quarter. Capital World Investors now owns 27,899,903 shares of the medical equipment provider’s stock valued at $2,492,041,000 after purchasing an additional 6,216,199 shares in the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its position in Boston Scientific by 2.5% during the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 22,312,967 shares of the medical equipment provider’s stock valued at $1,992,994,000 after purchasing an additional 554,388 shares in the last quarter. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Price Performance

NYSE:BSX opened at $101.35 on Monday. Boston Scientific Corporation has a 12 month low of $71.88 and a 12 month high of $107.17. The company has a market capitalization of $149.95 billion, a P/E ratio of 73.98, a P/E/G ratio of 2.62 and a beta of 0.68. The business’s 50-day moving average is $101.77 and its 200 day moving average is $99.17. The company has a current ratio of 1.45, a quick ratio of 0.88 and a debt-to-equity ratio of 0.47.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.67 by $0.08. Boston Scientific had a net margin of 11.58% and a return on equity of 18.67%. The business had revenue of $4.66 billion during the quarter, compared to analysts’ expectations of $4.57 billion. During the same period last year, the company posted $0.56 EPS. The business’s revenue was up 20.9% on a year-over-year basis. On average, equities research analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Boston Scientific news, CEO Michael F. Mahoney sold 164,443 shares of the business’s stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $102.48, for a total transaction of $16,852,118.64. Following the sale, the chief executive officer now directly owns 1,535,706 shares of the company’s stock, valued at $157,379,150.88. The trade was a 9.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP John Bradley Sorenson sold 4,572 shares of the business’s stock in a transaction that occurred on Monday, May 5th. The stock was sold at an average price of $104.54, for a total value of $477,956.88. Following the sale, the executive vice president now directly owns 18,705 shares in the company, valued at $1,955,420.70. The trade was a 19.64% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 411,970 shares of company stock valued at $42,406,693 over the last ninety days. 0.50% of the stock is owned by insiders.

Analysts Set New Price Targets

Several research firms recently weighed in on BSX. Evercore ISI lifted their target price on Boston Scientific from $110.00 to $112.00 and gave the company an “outperform” rating in a research report on Thursday, April 24th. Wall Street Zen upgraded Boston Scientific from a “hold” rating to a “buy” rating in a research report on Tuesday, April 29th. Robert W. Baird boosted their price objective on Boston Scientific from $115.00 to $120.00 and gave the company an “outperform” rating in a research report on Thursday, April 24th. BTIG Research restated a “buy” rating and issued a $124.00 price objective on shares of Boston Scientific in a research report on Wednesday, April 23rd. Finally, Morgan Stanley boosted their price objective on Boston Scientific from $120.00 to $125.00 and gave the company an “overweight” rating in a research report on Friday, May 16th. Twenty-two research analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $116.09.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.